Dataset Information

Genetic evidence for association of NOTCH4 variant rs2071287 with schizophrenia susceptibility in the North Indian population.

ABSTRACT:

Background

Neurogenic locus notch homolog 4 (NOTCH4) regulates signaling pathways associated with neuronal maturation, a process involved in the development and patterning of the central nervous system. The NOTCH4 gene has also been identified as a possible susceptibility gene for schizophrenia (SCZ).

Aim

The study aimed to determine the association of NOTCH4 polymorphisms with the risk of SCZ in the North Indian population of the Jammu region.

Methods

The single nucleotide polymorphism genotyping for NOTCH4 variant rs2071287 was done by Sanger's sequencing method, and the other variant rs3131296 was done by TaqMan assay method for 207 SCZ cases and 304 healthy controls of North Indian origin.

Results

This association study suggested that the rs2071287 was found to be significantly associated with SCZ. Moreover, the GG genotype of rs2071287 was observed to be associated with a higher risk for SCZ (P-value = 6.45 × 10 ^{- 5}; OR = 1.71; 95% CI, 1.31-2.24).

Conclusion

To establish the potential biomarker role of this variant, large-scale association analyses in other populations is required.

SUBMITTER: Priya I

PROVIDER: S-EPMC9881712 | biostudies-literature | 2022 Nov-Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Genetic evidence for association of <i>NOTCH4</i> variant rs2071287 with schizophrenia susceptibility in the North Indian population.

Priya Indu I Arora Manu M Singh Hemender H Sharma Isar I Mahajan Ritu R Kapoor Nisha N

Indian journal of psychiatry 20221130 6

<h4>Background</h4>Neurogenic locus notch homolog 4 (<i>NOTCH4</i>) regulates signaling pathways associated with neuronal maturation, a process involved in the development and patterning of the central nervous system. The <i>NOTCH4</i> gene has also been identified as a possible susceptibility gene for schizophrenia (SCZ).<h4>Aim</h4>The study aimed to determine the association of <i>NOTCH4</i> polymorphisms with the risk of SCZ in the North Indian population of the Jammu region.<h4>Methods</h4> ...[more]

PMID: 36714673

Similar Datasets

Project description:CYP2E1 is a member of the cytochrome P450 superfamily, which is involved in the metabolism and activation of both endobiotics and xenobiotics. The genetic polymorphisms of CYP2E1 gene (Chromosome 10q26.3, Accession Number NC_000010.10) are reported to be related to the development of several mental diseases and to be involved in the clinical efficacy of some psychiatric medications. We investigated the possible association of CYP2E1 polymorphisms with susceptibility to schizophrenia in the Chinese Han Population as well as the relationship with response to risperidone in schizophrenia patients.In a case-control study, we identified 11 polymorphisms in the 5' flanking region of CYP2E1 in 228 schizophrenia patients and 384 healthy controls of Chinese Han origin. From among the cases, we chose 130 patients who had undergone 8 weeks of risperidone monotherapy to examine the relationship between their response to risperidone and CYP2E1 polymorphisms. Clinical efficacy was assessed using the Brief Psychiatric Rating Scale (BPRS).Statistically significant differences in allele or genotype frequencies were found between cases and controls at rs8192766 (genotype p?=?0.0048, permutation p?=?0.0483) and rs2070673 (allele: p?=?0.0018, permutation p?=?0.0199, OR?=?1.4528 95%CI?=?1.1487-1.8374; genotype: p?=?0.0020, permutation p?=?0.0225). In addition, a GTCAC haplotype containing 5 SNPs (rs3813867, rs2031920, rs2031921, rs3813870 and rs2031922) was observed to be significantly associated with schizophrenia (p?=?7.47E-12, permutation p<0.0001). However, no association was found between CYP2E1 polymorphisms/haplotypes and risperidone response.Our results suggest that CYP2E1 may be a potential risk gene for schizophrenia in the Chinese Han population. However, polymorphisms of the CYP2E1 gene may not contribute significantly to individual differences in the therapeutic efficacy of risperidone. Further studies in larger groups are warranted to confirm our results.